Evidence map›Paper›PMID 41908948›Full record

ArticleDrug design, development and therapy2026

Synthesis and Biological Evaluation of Imidazopyridine-Isatin Hybrids as Inhibitors of

Mahmoud A El Hassab, Wagdy M Eldehna, Zainab M Elsayed, Mostafa M Elbadawi, Ahmed T Negmeldin, Marwa Balaha, Sherry N Nasralla, Rehan Monir, Tamer M Ibrahim, Manabu Abe and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mahmoud A El HassabDepartment of Medicinal Chemistry, Faculty of Pharmacy, King Salman International University (KSIU), South Sinai, Egypt.
Wagdy M EldehnaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.ORCID 0000-0001-6996-4017
Zainab M ElsayedScientific Research and Innovation Support Unit, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.ORCID 0009-0005-6913-356X
Mostafa M ElbadawiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
Ahmed T NegmeldinDepartment of Pharmaceutical Sciences, College of Pharmacy and Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman, United Arab Emirates.
Marwa BalahaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
Sherry N NasrallaPharmacy Program, Allied Health Department, College of Health and Sport Sciences, University of Bahrain, Salmaniya, Bahrain.
Rehan MonirClinical Biochemistry Department, College of Medicine, King Khalid University, Asir, Saudi Arabia.
Tamer M IbrahimDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
Manabu AbeDepartment of Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, Hiroshima, Japan.
Haytham O TawfikDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.ORCID 0000-0001-6455-5716
Adnan A BekhitPharmacy Program, Allied Health Department, College of Health and Sport Sciences, University of Bahrain, Salmaniya, Bahrain.ORCID 0000-0003-3865-0677
Loah R HemedaDepartment of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: More than 20 different species of Leishmania cause leishmaniasis, a multifaceted disease that ranges from mild cutaneous lesions to fatal visceral forms. Methods: Sixteen novel hybrids were designed by covalently linking an imidazo[1,2- Results: Several compounds showed potent anti-leishmanial activity compared to miltefosine, with the lead compound Conclusion: These findings highlight a promising new chemotype targeting the leishmanial folate pathway and expand the chemical diversity available for anti-leishmanial drug development.

Indexed as

Antiprotozoal AgentsImidazolesIsatinLeishmania majorPyridinesAnimalsDose-Response Relationship, DrugHumansMolecular Docking SimulationMolecular StructureParasitic Sensitivity TestsStructure-Activity RelationshipAntiprotozoal AgentsImidazolesimidazopyridineIsatinPyridinesanti-folate mechanismimidazo[1,2-a]pyridineisatinleishmaniasismolecular modelingneglected tropical diseases

Identifiers

PMID41908948
PMCPMC13032738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.